PubMed:34305404 / 0-194 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/34305404","sourcedb":"PubMed","sourceid":"34305404","source_url":"https://www.ncbi.nlm.nih.gov/pubmed/34305404","text":"Targeting Neuroinflammation via Purinergic P2 Receptors for Disease Modification in Drug-Refractory Epilepsy.\nTreatment of epilepsy remains a clinical challenge, with \u003e30% of patients not respon","tracks":[{"project":"Inflammaging","denotations":[{"id":"T1","span":{"begin":0,"end":109},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":109},"obj":"Sentence"}],"attributes":[{"subj":"T1","pred":"source","obj":"Inflammaging"},{"subj":"T1","pred":"source","obj":"Inflammaging"}]},{"project":"sonoma","denotations":[{"id":"T0","span":{"begin":0,"end":9},"obj":"REG"},{"id":"T1","span":{"begin":10,"end":27},"obj":"CPA"},{"id":"T2","span":{"begin":68,"end":80},"obj":"REG"},{"id":"T3","span":{"begin":84,"end":108},"obj":"DISEASE"},{"id":"T4","span":{"begin":123,"end":131},"obj":"DISEASE"},{"id":"T5","span":{"begin":184,"end":187},"obj":"NEGREG"}],"relations":[{"id":"R0","pred":"CauseOf","subj":"T0","obj":"T2"},{"id":"R1","pred":"ThemeOf","subj":"T1","obj":"T0"},{"id":"R2","pred":"ThemeOf","subj":"T3","obj":"T0"},{"id":"R3","pred":"ThemeOf","subj":"T3","obj":"T2"},{"id":"R4","pred":"ThemeOf","subj":"T4","obj":"T5"}],"attributes":[{"subj":"T0","pred":"source","obj":"sonoma"},{"subj":"T1","pred":"source","obj":"sonoma"},{"subj":"T2","pred":"source","obj":"sonoma"},{"subj":"T3","pred":"source","obj":"sonoma"},{"subj":"T4","pred":"source","obj":"sonoma"},{"subj":"T5","pred":"source","obj":"sonoma"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"Inflammaging","color":"#ec9e93","default":true},{"id":"sonoma","color":"#93a1ec"}]}]}}